


+ Evidence in focus

Publication summary: Mullins RF, et al. *Wounds* (2020)*

Use of STRAVIX[◇] Cryopreserved Umbilical Tissue helped achieve complete granulation in the majority of patients with acute and chronic complex wounds in a pilot study

+ Plus points




Overview

- Prospective, open-label, pilot study conducted at a single center to analyze the use of STRAVIX Tissue in the treatment of acute and chronic complex wounds
- Patients (N=10) with 12 wounds (average area, 16.5cm²; average duration, 10 months) received one application of STRAVIX Tissue
 - Wounds were cleaned and debrided prior to application
- Of the 12 wounds there were: 4 diabetic foot ulcers, 2 venous leg ulcers, 3 trauma wounds, 2 pressure ulcers and 1 surgical wound
- Patients were followed up weekly for 4 weeks post application
 - Ten wounds were included in the final analysis as two patients did not complete the study

Results

- Eight of the 10 wounds achieved complete granulation in a median time of 13 days (Figure)
- At 4 weeks post application of STRAVIX Tissue, the median percent area wound reduction was 40.5% and the median volume percent reduction was 59.4%
- In total, 30% of wounds achieved complete closure 4 weeks post application of STRAVIX Tissue (3 of 10 wounds)



Conclusions

Use of STRAVIX Tissue helped to achieve complete granulation in the majority of acute and chronic complex wounds with some achieving complete closure within the 4-week study.

Citation

*Mullins RF, Hassan Z, Homsombath B, et al. Prospective, single-center, open-label, pilot study using cryopreserved umbilical tissue containing viable cells in the treatment of complex acute and chronic wounds. *Wounds*. 2020;32(8):221–227.

Available at: [Wounds](#)

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.